GNS-3545 (ROCK2 Inhibitor)
Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Genosco
Genosco is a U.S.-based, clinical-stage biotech founded in 2018 with a core focus on kinase-targeted therapies. The company's differentiation lies in its proprietary discovery platform, GENO-K™/GENO-D™, designed to identify rare kinase sequences and develop selective inhibitors and protein degraders. Its pipeline includes both internally discovered assets and partnered programs, with lead candidates like a ROCK2 inhibitor entering Phase 1 and a legacy asset, lazertinib, already approved in combination therapies. The company appears to be a subsidiary of Oscotec Inc. and operates with a mix of independent R&D and strategic partnerships.
View full company profileAbout Genosco
Genosco is a U.S.-based, clinical-stage biotech founded in 2018 with a core focus on kinase-targeted therapies. The company's differentiation lies in its proprietary discovery platform, GENO-K™/GENO-D™, designed to identify rare kinase sequences and develop selective inhibitors and protein degraders. Its pipeline includes both internally discovered assets and partnered programs, with lead candidates like a ROCK2 inhibitor entering Phase 1 and a legacy asset, lazertinib, already approved in combination therapies. The company appears to be a subsidiary of Oscotec Inc. and operates with a mix of independent R&D and strategic partnerships.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |
| LASN01 | Lassen Therapeutics | Preclinical |